Unlikely allies MSD, Cipla link to co-market Isentress in India
This article was originally published in Scrip
Executive Summary
MSD (as Merck & Co is known outside the US and Canada) and Cipla, never really considered natural allies, have now formed an India-specific partnership, under which Cipla will co-market the US firm's HIV drug Isentress (raltegravir).
You may also be interested in...
Roche Primes New Push Via Cipla For Avastin, Actemra In India
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the
More Pressure On Pharma: UN Report Backs Compulsory Licensing
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.